This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Nicotinamide riboside
- DrugBank Accession Number
- DB14933
- Background
Nicotinamide riboside is under investigation in clinical trial NCT03432871 (Nicotinamide Riboside and Mitochondrial Biogenesis).
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Nicotinamide riboside (DB14933)
- Weight
- Average: 255.2472
Monoisotopic: 255.0980966 - Chemical Formula
- C11H15N2O5
- Synonyms
- Not Available
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 0I8H2M0L7N
- CAS number
- 1341-23-7
- InChI Key
- JLEBZPBDRKPWTD-TURQNECASA-O
- InChI
- InChI=1S/C11H14N2O5/c12-10(17)6-2-1-3-13(4-6)11-9(16)8(15)7(5-14)18-11/h1-4,7-9,11,14-16H,5H2,(H-,12,17)/p+1/t7-,8-,9-,11-/m1/s1
- IUPAC Name
- 3-carbamoyl-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1lambda5-pyridin-1-ylium
- SMILES
- NC(=O)C1=C[N+](=CC=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0000855
- KEGG Compound
- C03150
- ChemSpider
- 388956
- ChEBI
- 15927
- ChEMBL
- CHEMBL438497
- ZINC
- ZINC000004096036
- PDBe Ligand
- NNR
- Wikipedia
- Nicotinamide_riboside
- PDB Entries
- 2qt0 / 2qt1 / 4qtn / 6gye
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Treatment Healthy Subjects (HS) 1 4 Not Yet Recruiting Other Aging 1 4 Recruiting Treatment Coronavirus Disease 2019 (COVID‑19) / Sequelae of; Infection / Symptoms, Cognitive 1 3 Recruiting Treatment Peripheral Arterial Disease (PAD) 1 2 Active Not Recruiting Treatment Acute Kidney Injury (AKI) / Coronavirus Disease 2019 (COVID‑19) 1 2 Recruiting Prevention Acute Kidney Injury (AKI) 1 2 Recruiting Prevention Small Fibre Neuropathy 1 2 Recruiting Treatment Aging / Hypertension 1 2 Recruiting Treatment Blood Pressures / Kidney Diseases / Stress Oxidative / Vascular Diseases 1 2 Recruiting Treatment Chemotherapy Induced Peripheral Neuropathy (CIPN) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 5.45 mg/mL ALOGPS logP -2.3 ALOGPS logP -6.1 Chemaxon logS -1.7 ALOGPS pKa (Strongest Acidic) 11.39 Chemaxon pKa (Strongest Basic) -1.6 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 4 Chemaxon Polar Surface Area 116.89 Å2 Chemaxon Rotatable Bond Count 3 Chemaxon Refractivity 60.83 m3·mol-1 Chemaxon Polarizability 24.83 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-0a4i-0090000000-e25d1beb47cb1fe9e4cb Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-002b-3090000000-03687e9ef697eda1d6c8 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-052g-9300000000-2755bde4df843d2227f2 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-0udi-0090000000-809be1146b2a2c8d96a7 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-0udi-1390000000-2fc72cf0619f182e044f Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-0k96-9300000000-4d5b96b192f3484b1b8a
Drug created at May 20, 2019 14:36 / Updated at June 12, 2020 16:53